IC
KYMR icon

Innealta Capital’s Kymera Therapeutics KYMR Stock Holding History

Innealta Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-44
Closed -$1.31K – 978
2024
Q2 		$1.31K Buy
+44
New +$1.52K ﹤0.01% 1233

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Innealta Capital's KYMR Position: Q3 2024 in Review

Innealta Capital sold out of Kymera Therapeutics (KYMR) in Q3 2024, closing a stake of 44 shares — an estimated $1.31K sold.

Innealta Capital first reported a position in KYMR in Q2 2024 and held it in 1 quarter. The position peaked at $1.31K in Q2 2024. 176 funds tracked by Wall St. Rank hold KYMR as of Q3 2024.

  • Innealta Capital reported no remaining Kymera Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 44 Kymera Therapeutics shares in Q3 2024, an estimated $1.31K.
  • Innealta Capital first reported a position in Kymera Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Kymera Therapeutics position peaked at $1.31K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.